ALK and neuroblastoma: Employing anti-p-Y1000 immunoprecipitation, we were able to show that MARCH11 was tyrosine phosphorylated in ALK-mutant NB cells, and that this was decreased upon treatment with the ALK inhibitor, lorlatinib (Fig. 2G, Sup.